408 related articles for article (PubMed ID: 30957510)
21. Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
Cañas F; Möller HJ
Expert Opin Drug Saf; 2010 Sep; 9(5):683-97. PubMed ID: 20690885
[TBL] [Abstract][Full Text] [Related]
22. Long-acting injectable antipsychotics in the elderly: guidelines for effective use.
Masand PS; Gupta S
Drugs Aging; 2003; 20(15):1099-110. PubMed ID: 14651433
[TBL] [Abstract][Full Text] [Related]
23. Long-Acting Injectable Antipsychotics for Prevention of Relapse in Bipolar Disorder: A Systematic Review and Meta-Analyses of Randomized Controlled Trials.
Kishi T; Oya K; Iwata N
Int J Neuropsychopharmacol; 2016 Sep; 19(9):. PubMed ID: 27207910
[TBL] [Abstract][Full Text] [Related]
24. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
Morris MT; Tarpada SP
Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271
[TBL] [Abstract][Full Text] [Related]
25. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
Kane JM; Leucht S; Carpenter D; Docherty JP;
J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
[TBL] [Abstract][Full Text] [Related]
26. The effect of long-acting injectable antipsychotic medications compared with oral antipsychotic medications among people with schizophrenia: A systematic review and meta-analysis.
Okoli CTC; Kappi A; Wang T; Makowski A; Cooley AT
Int J Ment Health Nurs; 2022 Jun; 31(3):469-535. PubMed ID: 34931437
[TBL] [Abstract][Full Text] [Related]
27. Mortality Risk Associated With Long-acting Injectable Antipsychotics: A Systematic Review and Meta-analyses of Randomized Controlled Trials.
Kishi T; Matsunaga S; Iwata N
Schizophr Bull; 2016 Nov; 42(6):1438-1445. PubMed ID: 27086079
[TBL] [Abstract][Full Text] [Related]
28. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
[TBL] [Abstract][Full Text] [Related]
29. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
30. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.
Bhanji NH; Chouinard G; Margolese HC
Eur Neuropsychopharmacol; 2004 Mar; 14(2):87-92. PubMed ID: 15013023
[TBL] [Abstract][Full Text] [Related]
31. Long-acting injectable antipsychotics in early psychosis: a literature review.
Emsley R; Chiliza B; Asmal L; Mashile M; Fusar-Poli P
Early Interv Psychiatry; 2013 Aug; 7(3):247-54. PubMed ID: 23342964
[TBL] [Abstract][Full Text] [Related]
32. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics.
Chue P; Emsley R
CNS Drugs; 2007; 21(6):441-8. PubMed ID: 17521224
[TBL] [Abstract][Full Text] [Related]
33. Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia.
Correll CU; Lauriello J
J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32609958
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of second-generation long-acting injections in schizophrenia: a meta-analysis of randomized-controlled trials.
Fusar-Poli P; Kempton MJ; Rosenheck RA
Int Clin Psychopharmacol; 2013 Mar; 28(2):57-66. PubMed ID: 23165366
[TBL] [Abstract][Full Text] [Related]
35. Long-Acting Injectable Antipsychotics and Infections in Schizophrenia.
Malham KM; Miller BJ
J Clin Psychopharmacol; 2023 May-Jun 01; 43(3):259-262. PubMed ID: 37067982
[TBL] [Abstract][Full Text] [Related]
36. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
39. Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials.
Leucht C; Heres S; Kane JM; Kissling W; Davis JM; Leucht S
Schizophr Res; 2011 Apr; 127(1-3):83-92. PubMed ID: 21257294
[TBL] [Abstract][Full Text] [Related]
40. Model of Management (Mo.Ma) for the patient with schizophrenia: crisis control, maintenance, relapse prevention, and recovery with long-acting injectable antipsychotics (LAIs).
Brugnoli R; Rapinesi C; Kotzalidis GD; Marcellusi A; Mennini FS; De Filippis S; Carrus D; Ballerini A; Francomano A; Ducci G; Del Casale A; Girardi P
Riv Psichiatr; 2016; 51(2):47-59. PubMed ID: 27183509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
